A phase II study of pegfilgrastim to support ACE 14 chemotherapy for the treatment of subjects with small cell lung cancer (SCLC; extensive disease)

Pirker, R.; Ulsperger, E.; Aigner, K; Messner, J.

doi:10.1200/jco.2004.22.14_suppl.7216

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For almost all patients, the serum concentration of pegfilgrastim became subtherapeutic by day 11 or 12, and this was strongly predicted by a post-nadir ANC ≥ 1 × 10 9 cells/l. Several Phase I and Phase II trials have demonstrated the safe and effective use of pegfilgrastim to support a variety of chemotherapy regimens with 14-day intervals for treatment of non-Hodgkin's lymphoma [54,55], Hodgkin's disease [56,57], early-stage breast cancer [58,59] and small cell lung cancer [60] ( Table 3). A randomised study was designed to compare the efficacy of pegfilgrastim 6 mg (n = 32) versus filgrastim 5 µg/kg/day (n = 26) as an adjunct to CHOP plus rituximab given every 2 weeks in aggressive non-Hodgkin's lymphoma [61].…”

Section: Pegfilgrastim With 14-day Regimensmentioning

confidence: 99%

Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action

Lyman¹

2005

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Granulocyte colony-stimulating factors such as filgrastim (Neupogen, Amgen, Inc.) and pegfilgrastim (Neulasta, Amgen, Inc.) are frequently used in clinical practice for the prevention of chemotherapy-induced neutropenia and its potentially life-threatening complications. Due to its unique neutrophil-mediated clearance, pegfilgrastim can be administered once per chemotherapy cycle. Clinical trials have shown that a single, fixed subcutaneous dose of pegfilgrastim 6 mg is comparable in safety and efficacy to daily injections of filgrastim for decreasing the incidence of infection following myelosuppressive chemotherapy in patients with cancer. Postregistrational trials have been conducted to evaluate the use of pegfilgrastim with emerging dose-dense regimens, in myeloid cancers and for mobilisation and engraftment of autologous stem cells. Ongoing clinical trials continue to explore further potential uses for pegfilgrastim.

show abstract

Section: Pegfilgrastim With 14-day Regimensmentioning

confidence: 99%

Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action

Lyman¹

2005

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

show abstract

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy

Green

2005

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

The advent of granulocyte colony-stimulating factor, in particular filgrastim, in clinical use more than 10 years ago made a significant impact on the management of neutropenia and its complications. More recently, the application of pegylation technology has created a second-generation molecule, pegfilgrastim, with significantly altered pharmacokinetic properties. This has allowed for a once per chemotherapy cycle dosing in contrast to the requirement of daily subcutaneous administration for filgrastim. Several randomized trials in nonmyeloid malignancies have proven that a fixed dose of pegfilgrastim 6 mg is at least equivalent to daily filgrastim therapy. Emerging evidence also suggests that pegfilgrastim may be equally employed in the setting of chemotherapy for acute myeloid leukemia, dose-dense chemotherapy and peripheral stem cell mobilization. If confirmed in subsequent Phase III trials, it is likely that pegfilgrastim will eventually succeed filgrastim as the colony-stimulating factor of choice in clinical practice.

show abstract

A phase II study of pegfilgrastim to support ACE 14 chemotherapy for the treatment of subjects with small cell lung cancer (SCLC; extensive disease)

Cited by 2 publications

References 0 publications

Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action

Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action

Pegfilgrastim: evidence in support of its use with cytotoxic chemotherapy

Contact Info

Product

Resources

About